Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase

Blood

Volumn 96, Issue 1, 2000, Pages 358-361

  Boultwood, Jackie ^a   Peniket, Andrew ^b   Watkins, Fiona ^b   Shepherd, Patricia ^b   McGale, Paul ^b   Richards, Susan ^b   Fidler, Carrie ^b   Littlewood, Timothy J ^b   Wainscoat, James S ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TELOMERE;

EID: 0034235119     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.1.358     Document Type: Article

References (20)

1. Blackburn EH. Structure and function of telomeres. Nature. 1991;350:569-573.
2. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 1995; 85:2315-2320.
3. Hastie ND, Dempster M. Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 1990;46:866-868.
4. Ducray C, Pommier JP, Martins L, Boussin FD, Sabatier L Telomere dynamics, end-to-end fusions and telomerase activation during the human fibroblast immortalization process. Oncogene. 1999;18:4211-4223.
5. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994; 266:2011-2015.
6. Hiyama E, Gollahon L, Kataoka T, et al. Telomerase activity in human breast tumors. J Natl Cancer Inst. 1996;88:116-122.
7. Ohyashiki JH, Ohyashiki K, Fujimura T, et al. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res. 1994;54:3557-3560.
8. Ohyashiki JH, Ohyashiki K, Iwama H, Hayashi S, Shay JW, Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia. 1997;11: 190-194.
9. Ohyashiki JH, Iwama H, Yahata N, et al. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res. 1999;5:1155-1160.
10. Boultwood J, Fidler C, Kusec R, et al. Telomere length in the myelodysplastic syndromes. Am J Hematol. 1997;56:266-271.
11. Boultwood J, Fidler C, Shepherd P, et al. Telomere length shortening is associated with disease evolution in chronic myelogenous leukaemia. Am J Hematol. 1999;61:5-9.
12. Ball SE, Gibson FM, Fizzo S, Tooze JA, Marsh JCW, Gordon-Smith EC. Progressive telomere shortening in aplastic anaemia. Blood. 1998;91: 3582-3592.
13. Bechter OE, Eisterer W, Pall G, Hilbe W, Kuhr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B-cell chronic lymphocytic leukaemia. Cancer Res. 1999;58:4918-4922.
14. Allan NC, Richards SM, Shepherd PCA. UK Medical Research Council randomised, multicentre trial of interferon-alpha 1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet. 1995;345:1392-1397.
15. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukaemia: a concise update. Blood. 1993;82:691-703.
16. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring, NY: Cold Spring Harbor Laboratory Press: 1989.
17. Yamada O, Oshimi K, Motoji T, Miozoguchi H. Telomeric DNA in normal and leukemic blood cells. J Clin Invest. 1995;95:1117-1123.
18. Wynn RF, Cross MA, Hatton C, et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet. 1998;351: 178-181.
19. Iwama I, Ohyashiki K, Ohyashiki JH, et al. The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukaemia. Cancer. 1997;79:1552-1560.
20. Brummendorf TH, Holyoake TL, Rufer N, et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leuakemia measured by flow cytometry. Blood. 2000;95:1883-1890.